Cargando…

TKI rotation-induced persistent deep molecular response in multi-resistant blast crisis of Ph+ CML

In chronic myeloid leukemia (CML) resistance against one or more BCR-ABL1 tyrosine kinase inhibitors (TKI) remains a clinical challenge. Preclinical data suggest that TKI combinations may overcome resistance. We report on a heavily pre-treated 78 year-old female patient with CML who developed multi-...

Descripción completa

Detalles Bibliográficos
Autores principales:	Valent, Peter, Herndlhofer, Susanne, Schneeweiß, Mathias, Boidol, Bernd, Ringler, Anna, Kubicek, Stefan, Gleixner, Karoline V., Hoermann, Gregor, Hadzijusufovic, Emir, Müllauer, Leonhard, Sperr, Wolfgang R., Superti-Furga, Giulio, Mannhalter, Christine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5410285/ https://www.ncbi.nlm.nih.gov/pubmed/28416739 http://dx.doi.org/10.18632/oncotarget.15481

Ejemplares similares

CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019)

Incidence of symptomatic Covid‐19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population
por: Graf, Irene, et al.
Publicado: (2022)

The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis
por: Schneeweiss, Mathias, et al.
Publicado: (2018)

Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Immunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
por: Valent, Peter, et al.
Publicado: (2019)

PVR and ICAM-1 on Blast Crisis CML Stem and Progenitor Cells with TKI Resistance Confer Susceptibility to NK Cells
por: Kim, Nayoung, et al.
Publicado: (2020)

Blast Crisis of CML After TKI Discontinuation in a Patient With Previous Stable Deep Molecular Response: Is It Safe to Stop?
por: Papalexandri, Apostolia, et al.
Publicado: (2018)

Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site
por: Hadzijusufovic, Emir, et al.
Publicado: (2017)

FLAG-induced remission in a patient with acute mast cell leukemia (MCL) exhibiting t(7;10)(q22;q26) and KIT D816H()
por: Valent, Peter, et al.
Publicado: (2013)

Extramedullary blast crisis of secondary CML accompanying marrow fibrosis
por: Go, Jai Hyang, et al.
Publicado: (2012)

Growth effect of tki treatment in childhood CML
por: Jeon, Yeon Jin, et al.
Publicado: (2015)

Is There a Role for Dose Modification of TKI Therapy in CML?
por: Copland, M.
Publicado: (2019)

BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report
por: Ostendorf, Benjamin N, et al.
Publicado: (2015)

N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia
por: Wedeh, Ghaith, et al.
Publicado: (2015)

Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014)

Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML)
por: Herrmann, Harald, et al.
Publicado: (2012)

Drug Therapy in the Progressed CML Patient with multi-TKI Failure
por: Haznedaroglu, Ibrahim C.
Publicado: (2015)

Co-occurrence of CML Blast Crisis and Severe COVID 19 Infection: A Case Report
por: Khaja, Misbahuddin, et al.
Publicado: (2022)

Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
por: Heinemann, Tim, et al.
Publicado: (2022)

ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2015)

Ludwig Boltzmann Cluster Oncology (LBC ONC): first 10 years and future perspectives
por: Valent, Peter, et al.
Publicado: (2018)

Hoxa9 and Hoxa10 induce CML myeloid blast crisis development through activation of Myb expression
por: Negi, Vijay, et al.
Publicado: (2017)

Correction to: ARE/SUZ12 dual specifically-regulated adenoviral TK/GCV system for CML blast crisis cells
por: Zu, Bailing, et al.
Publicado: (2022)

Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56(bright) NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
por: Cuapio, Angélica, et al.
Publicado: (2016)

Aplasia in Chronic Phase CML Post-TKI Therapy: A Management Dilemma
por: Ramdial, Jeremy L., et al.
Publicado: (2019)

Combination of PKCδ Inhibition with Conventional TKI Treatment to Target CML Models
por: Muselli, Fabien, et al.
Publicado: (2021)

CDK4/CDK6 Inhibitors Synergize with Midostaurin, Avapritinib, and Nintedanib in Inducing Growth Inhibition in KIT D816V(+) Neoplastic Mast Cells
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

The Combination of Interferon-Alpha and Ponatinib Enables Faster and Deeper Molecular Responses in Patient with De Novo Blast Crisis of CML: Interferon-Alpha May Return as a CML Treatment
por: Hayashi, Kunio, et al.
Publicado: (2021)

MR-1 blocks the megakaryocytic differentiation and transition of CML from chronic phase to blast crisis through MEK dephosphorylation
por: Zhao, W, et al.
Publicado: (2013)

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia
por: Heller, G, et al.
Publicado: (2016)

The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib
por: Masiello, David, et al.
Publicado: (2009)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

Monitoring of immunity against leukemia stem cell in CML patients after cessation of TKI
por: Matsushita, Maiko, et al.
Publicado: (2015)

Evaluation of efficacy of alemtuzumab in 5 patients with aplastic anemia and/or myelodysplastic neoplasm
por: Füreder, Wolfgang, et al.
Publicado: (2016)

Molecular quantification of tissue disease burden is a new biomarker and independent predictor of survival in mastocytosis
por: Greiner, Georg, et al.
Publicado: (2020)

Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature Review
por: Morozova, E.V., et al.
Publicado: (2015)

Phenotyping and Target Expression Profiling of CD34(+)/CD38(−) and CD34(+)/CD38(+) Stem- and Progenitor cells in Acute Lymphoblastic Leukemia
por: Blatt, Katharina, et al.
Publicado: (2018)

Blast Crisis
por: Kirwin, Margaret, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rpvfvvpqpt62r21seth7u2g7ao